MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.conctc.2023.101074

Медицинская библиотека · Contemporary clinical trials communications · 2023

Design of a multicenter randomized clinical trial for treatment of Alcohol-Associated Hepatitis.

Tu Wanzhu, Gawrieh Samer, Dasarathy Srinivasan, Mitchell Mack C, Simonetto Douglas A, Patidar Kavish R, McClain Craig J, Bataller Ramon, Szabo Gyongyi, Tang Qing, Barton Bruce A, Radaeva Svetlana, Sanyal Arun J, Shah Vijay, Alcoholic Hepatitis Network (AlcHepNet) Investigators

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Mortality is high for severe alcohol-associated hepatitis (AH). Corticosteroids are the standard of care for patients without contraindications. Recent data showed that interleukin-1β receptor antagonist anakinra attenuated inflammation and liver damage. We designed a multicenter, double-blind, randomized controlled trial to assess the safety and efficacy of anakinra compared to prednisone.

METHODS

Patients meeting the clinical and biochemical criteria for severe AH with MELD scores between 20 and 35 were recruited at eight clinical sites. Eligible patients enrolled in the study were randomized to anakinra, 100 mg subcutaneous injection for 14 days, plus zinc sulfate 220 mg for 90 days, vs. prednisone 40 mg PO daily for 30 days. Matching placebos for anakinra, zinc, and prednisone were provided to mask the treatment. Participants were followed for 180 days. The primary outcome was overall survival at 90 days. An unadjusted log-rank test was used to compare the survival of the two treatments in the first 90 days. Between July 10, 2020, and March 4, 2022, we screened 1082 patients with severe AH, and 147 eligible patients were enrolled and randomized. The average baseline MELD score was 25 [range 20-35], Maddrey discriminant function (MDF) was 59.4 [range 20.2-197.5]. The mean aspartate transaminase (AST)-to-alanine transaminase (ALT) ratio was 3.5. The baseline characteristics were not statistically different between the two treatment groups.

CONCLUSIONS

The study provided a direct comparison of the survival benefits and safety profiles of anakinra plus zinc vs. prednisone in patients with severe AH.

Для цитирования: Tu Wanzhu, Gawrieh Samer, Dasarathy Srinivasan, Mitchell Mack C, Simonetto Douglas A, Patidar Kavish R, McClain Craig J, Bataller Ramon, Szabo Gyongyi, Tang Qing, Barton Bruce A, Radaeva Svetlana, Sanyal Arun J, Shah Vijay, Alcoholic Hepatitis Network (AlcHepNet) Investigators. Design of a multicenter randomized clinical trial for treatment of Alcohol-Associated Hepatitis.. Contemporary clinical trials communications. 2023. DOI: 10.1016/j.conctc.2023.101074.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.